Joel Selter, MD
Allergy/ Immunology · Suffern, NYNPI 1174526016
Payments from drug & device makers
Across 720 payments — averaging $117.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$72K
- Grifols USA, LLC$3K
- CSL Behring$1K
- GSK$1K
- Sanofi$798
- Novartis$698
- plus $5K from 26 others
What the payments were for
- Consulting fees$1,8152%
- Speaking & faculty fees$67,65080%
- Travel & lodging$1,6142%
- Food & beverage$13,18216%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 172 | $71,767 |
| Grifols USA, LLC | 31 | $3,147 |
| CSL Behring | 70 | $1,349 |
| GSK | 96 | $1,347 |
| Sanofi | 36 | $798 |
| Novartis | 45 | $698 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $641 |
| Biocryst US Sales Co., LLC | 35 | $583 |
| Pfizer | 34 | $543 |
| Regeneron Healthcare Solutions, Inc. | 19 | $533 |
| Genentech USA, Inc. | 19 | $332 |
| Pharming Healthcare, Inc. | 15 | $327 |
| Kaleo, Inc. | 16 | $325 |
| Amgen | 18 | $288 |
| Incyte Corporation | 4 | $196 |
| Optinose US, Inc. | 10 | $163 |
| Next Science LLC | 2 | $150 |
| Alk-abello, Inc | 4 | $148 |
| Ionis Pharmaceuticals, Inc. | 11 | $145 |
| Blueprint Medicines Corporation | 6 | $142 |
| Covis Pharma GmbH | 9 | $138 |
| Cycle Pharmaceuticals Inc | 4 | $121 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $92 |
| Boehringer Ingelheim | 4 | $85 |
| Merck | 4 | $60 |
| Sanofi-aventis U.S. LLC | 1 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Viatris Specialty LLC | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy/ immunology providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $224,732 |
| HyqviaIgg/Hyaluronidase,recombinant | 17 | $178,964 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,677 |
| Epinephrine | 17 | $3,405 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,002 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $1,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,284 |
| Mometasone Furoate | 17 | $991 |
| Azelastine Hcl | 41 | $892 |
| Fluticasone Propionate | 72 | $709 |
| Levocetirizine Dihydrochloride | 33 | $235 |
| Montelukast Sodium | 25 | $146 |
| Famotidine | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $1,349 | $224,73212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $641 | $178,96417 claims |
| GSKBreo Ellipta | $1,347 | $4,67712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in New Yorkon file to place this against a meaningful peer group, so we don't.
Other allergy/ immunology in Suffern
- Sebastian LighvaniNew York$93K
- Jessica SternRochester$5K
- David MenchellFresh Meadows$3K
- Michael LandorFlushing$2K
- Louis GuidaWest Bay Shore$795
- Craig OsleebMount Kisco$0
- Andrew ChangBrooklyn$0
- Avi DeenerWhite Plains$0
- Laura MechanicWhite Plains$0
- Gary WeinstockGreat Neck$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.